HIV-1 infection: Recent developments in treatment and current management strategies

Anti-Infective Agents in Medicinal Chemistry

Volumn 7, Issue 3, 2008, Pages 201-214

  Armbruster, Christine ^a,b  

^a 2nd Medical Department   (Austria)

^b NONE   (Austria)

Author keywords

Antiretroviral therapy; HIV 1 infection; Management strategies; Prevention

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; BEVIRIMAT; BILR 355; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PA 103001 04; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; TIPRANAVIR; UK 427 857; UNINDEXED DRUG; VICRIVIROC; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY FAT DISTRIBUTION; BONE MARROW SUPPRESSION; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG MONITORING; DRUG STRUCTURE; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; INJECTION SITE REACTION; INSULIN RESISTANCE; LIPID METABOLISM; LIPOATROPHY; LIPODYSTROPHY; LIVER TOXICITY; LOW DRUG DOSE; LYMPHADENOPATHY; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PATIENT COMPLIANCE; PHARYNGITIS; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VIRION; VIRUS LOAD; VIRUS REACTIVATION; VIRUS TRANSMISSION;

EID: 48249118406     PISSN: 18715214     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152108784911296     Document Type: Review

References (85)

1. UNAIDS/WHO. http://data.unaids.org/pub/EpiReport/2007/ 03-Introduction-2007_EpiUpdate_eng.pdf
2. UNAIDS/WHO. http://data.unaids.org/pub/EpiReport/2006/ 03-Introduedon-2006_EpiUpdate_eng.pdf
3. G8. Africa. www.fco.gov.uk/Files/kfile/PostG8_Gleneagles_Africa,0.pdf
4. Centers for Disease Control and Prevention. MMWR, 1992, 41 (No. RR-17).
5. Berger, A.; Scherzed, L.; Stürmer, M.; Preiser, W.; Doerr, H.W.; Rabenau, H.F. J. Clin. Virol., 2005, 33, 43-51.
6. Steindl, F.; Armbruster, C.; Pierer, K.; Purtscher, M.; Katinger, H.W. J. Immunol. Methods, 1998, 217, 143-151.
7. Soria, A.; Lazzarin, A. J. Acquir. Immune Defic. Syndr., 2007, 46 Suppl. 1, 19-30.
8. Lane, H.C.; Fauci, A.S. Annu. Rev. Immunol., 1985, 3, 477-500.
9. Maddon, P.J.; Dalgleish, A.G.; McDougal, J.S.; Clapham, P.R.; Weiss, R.A.; Axel, R. Cell, 1986, 47, 333-348.
10. Pantaleo, G.; Graziosi, C.; Fauci, A.S. N. Engl. J. Med., 1993, 328, 327-335.
11. Karzon, D.T. Preventive vaccines. In Textbook of AIDS Medicine; Broder, S.; Merigan, T.C.Jr.; Bolognesi, D., Eds.; Williams & Wilkins, 1994; pp. 667-692.
12. Masur, H.; Michelis, M.A.; Greene, J.B.; Onorato, I.; Stouwe, R.A.; Holzman, R.S.; Wormser, G.; Brettman, L.; Lange, M.; Murray, H.W.; Cunningham-Rundles, R. N. Engl. J. Med., 1981, 305, 1431-1438.
13. Van Marle, G.; Gill, M.J.; Kolodka, D.; McManus, L.; Grant, T.; Churg, D.L. Retrovirology, 2007, 4, 87. (Epub ahead of print)
14. Belmonte, L.; Olmos, M.; Fanin, A.; Parodi, C.; Bare, P.; Concetti, H.; Perez, H.; de Bracco, M.M.; Cahn, P. AIDS, 2007, 21, 2106-2108.
15. Le Tortorec, A.; Dejucq-Rainsford, N. Gynecol. Obstet. Fertil., 2007, Nov 20. (Epub ahead of print)
16. Ratner, L.; Haseltine, W.; Patarca, R.; Livak, K.J.; Starcich, B.; Josephs, S.F.; Doran, E.R.; Rafalski, J.A.; Whitehorn, E.A.; Baumeister, K.; Ivanoff, L.; Petteway, S.R.; Pearson, M.L.Jr.; Lautenberger, J.A.; Papas, T.S.; Ghrayeb, J.; Chang, N.T.; Gallo, R.C.; Wong-Staal, F. Nature, 1985, 313, 277-284.
17. Moyle, G.J.; Baldwin, C.; Landgroudi, B.; Mandalia, S.; Gazzard, B.G. J. Acquir. Immune Defic. Syndr., 2003, 33, 22-28.
18. Carr, A. AIDS, 2003, 17 Suppl, 1, S141-148.
19. Madruga, J.V.; Berger, D.; McMurchie, M.; Suter, F.; Banhegyi, D.; Ruxrungtham, K.; Norris, D.; Lefebvre, E.; de Bethune, M-P.; Tomaka, F.; De Pauw, M.; Vangeneugden, T.; Spinosa-Guzman S.; on behalf of the TITAN study group. Lancet, 2007, 370, 49-58.
20. Sanger, F.; Nicklen, S.; Coulson, A.R. Proc. Natl. Acad. Sci. USA, 1977, 74, 5463-5467.
21. Furman, P.A.; Fyfe, J.A.; St. Clair, M.H.; Weinhold, K.; Rideout, J.L.; Freeman, G.A.; Lehrman, S.N.; Bolognesi, D.P.; Broder, S.; Mitsuya, H.; on behalf the study group. Proc. Natl. Acad. Sci. USA, 1986, 83, 8333-8337.
22. Balzarini, J.; De Clercq, E. Biochemical pharmacology of nucleoside analogs active against HIV, In Textbook of AIDS Medicine; Broder, S.; Merigan, T.C.Jr.; Bolognesi, D., Eds.; Williams&Wilkins, 1994; pp.751-772.
23. Hasegawa, T.; Kawaguchi, T. Curr. Med. Chem.-Anti-Infective Agents, 2002, 1, 55-63.
24. Aweeka, F.; Lizak, P.; Frenkel, L.; An, S.; Watts, H.; McNamara, J.; Stevens, L.; Hitti, J.; PACTG 1022 Study Team. 11th Conference an Retroviruses and Opportunistic Infections, 2004, San Francisco, CA, abstract 932.
25. Weinstock, H.S.; Zaidi, I.; W. Heneine, W.; Bennett, D.; Garcia-Lerma, J.G.; Douglas, J.M.Jr.; LaLota, M.; Dickinson, G.; Schwarcz, S.; Torian, L.; Wendell, D.; Paul, S.; Goza, G.A.; Ruiz, J.; Boyett, B.; Kaplan, J.E. J. Infect. Dis., 2004, 189, 2174-2180.
26. Waters, L.; Boffito, M. Anti-Infective Agents Med. Chem., 2007, 6, 213-221.
27. Erickson, J.W. HIV-1 protease as a target for AIDS therapy, In Protease inhibitors in AIDS therapy; Ogden, R.C.; Flexner, C.W., Eds; Marcel Dekker, Inc.: New York, Basel, 2001; pp. 1-25.
28. Sommadossi, J.P. Antiviral Ther., 1998, 3, 9-12.
29. Barry, M.; Gibbons, S.; Back, D.; Mulcahy, F. Clin. Pharmacokinet., 1997, 32, 194-209.
30. Bilello, J.A.; Bilello, P.A.; Stellrecht, K.; Leonard, J.; Norbeck, D.W.; Kempf, D.J.; Robins, T.; Drusano, G.L. Antimicrob. Agents Chemother., 1996, 40, 1491-1497.
31. Washington, C.B.; Duran, G.E.; Man, M.C.; Sikic, B.J.; Blaschke, T.F. J. Acquir. Immune Defic. Syndr. Hum.Retrovirol., 1998, 19, 203-209.
32. Armbruster, C.; Vorbach, H.; Steindl, F.; El Menyawi, I. J. Antimicrab. Chemother., 2001, 47, 487-490.
33. Hicks, C.B.; Cahn, P.; Cooper, D.A.; Walmsley, S.L.; Katlama, C.; Clotet, B.; Lazzarin, A.; Johnson, M.A.; Neubacher, D.; Mayers, D.; Valdez, H.; RESIST investigator group. Lancet, 2006, 368, 466-475.
34. Cahn, P.; Villacian, J.; Lazzarin, A.; Katlama, C.; Grinsztejn, B.; Arasteh, K.; Lopez, P.; Clumeck, N.; Gerstoft, J.; Stavrianeas, N.; Moreno, S.; Antunes, F.; Neubacher, D.; Mayers, D. Clin. Infect. Dis., 2006, 43, 1347-1356.
35. Katlama, C.; Esposito, R.; Gatell, J.M.; Goffard, J.C.; Grinsztejn, B.; Pozniak, A.; Rockstroh, J.; Stoehr, A.; Vetter, N.; Yeni, P.; Parys, W.; Vangeneugden, T:, the POWER 1 study group. AIDS, 2007, 21, 395-402.
36. Clotet, B.; Bellos, N.; Molina, J.M.; on behalf the Power 1 and 2 study groups. Lancet, 2007, 369, 1169-1278.
37. Machado, E.S.; Passoni, L.F.; Sidi, L.C.; Andrade, H.B.; DE Menezes, J.A. AIDS, 2006, 20, 2130-2131.
38. Ray, N.; Harrison, J.E.; Blackburn, L.A.; Martin, J.N.; Deeks, S.G.; Doms, R.W. J. Virol., 2007, 81, 3240-3250.
39. AIDSinfo. http://www.aidsinfo.nih.gov/guidelines/ default.aspx?MenuItem=guidelines (accessed December 29th, 2007)
40. Madruga, J.V.; Cahn, P.; Grinsztejn, B.; Haubrich, R.; Lalezari, J.; Mills, A.; Pialoux, G.; Wilkin, T.; Peeters, M.; Vingerhoets, J.; de Smedt, G.; Leopold, L.; Trefiglio, R.; Woodfall, B.; DUET-1 study group. Lancet, 2007, 370, 29-38.
41. Lazzarin, A.; Campbell, T.; Clotet, B.; Johnson, M.; Katlama, C.; Moll, A.; Towner, W.; Trottier, B.; Peeters, M.; Vingerhoets, J.; de Smedt, G.; Baeten, B.; Beets, G.; Sinha, R.; Woodfall, B.; DUET-2 study group. Lancet, 2007, 370, 39-48.
42. Dejesus, E.; Ortiz, R.; Khanlu, H.; on behalf the study group. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2007, abstract H-718b.
43. Winston, A.; Mallon, P.W.; Satchell, C.; MacRae, K.; Williams, K.M.; Schutz, M.; Law, M.; Cooper, D.A.; Emery, S. Clin. Infect. Dis., 2007, 44, 1475-1483.
44. Gatell, J.; Salmon-Ceron, D.; Lazzarin, A.; Van Wijngaerden, E.; Antunes, F.; Leen, C.; Horban, A.; Wirtz, V.; Odeshoo, L.; Van den Dungen, L.M.; Gruber, C.; Ledesma, E.; SWAN Study Group. Clin. Infect Dis., 2007, 44, 1484-1492.
45. Lalezari, J.; Goodrich, J.; DeJesus, E.; Lampiris, H.; Gulick, R.; Saag, M.; Ridgway, C.; McHale, M.; van der Ryst, E; Mayer, H. MOTTVATE 1. USA and Canada. 14th Conference on Retroviruses and Opportunistic Infections, 2007, abstract 104bLB.
46. Nelson, M.; Fätkenheuer, G.; Konourina, I.; Lazzarin, A. Clumeck, N.; Horban, A.; Tawadrous, M.; Sullivan, J.; Mayer, H.; van der Ryst, E. MOTIVATE 2. Europe, Australia and USA. 14th Conference on Retroviruses and Opportunistic Infections, 2007, abstract 104aLB.
47. Este, J.A.; Telenti, A. Lancet, 2007, 370, 81-88.
48. Saag, M.S.; Jacobson, J.M.; Thompson, M.; Fischl, M.; Liporace, R.; Reichman, R.C.; Redfield, R.R.; Fichtenbaum, C.J.; Zingman, B.S.; Patel, M.C.; D'Ambrosio, P.; Michael, M.; Kroger, H.; Ly, H.; Rotshteyn, Y.; Stavola, J.J.; Maddon, P.J.; Kremer,A.B.; Olson, W.C. www.ias2007.org/ pag/Abstracts.aspx?SID=48&AID=3027.
49. Dayam, R.; Gundla, R.; Al-Mawsawi, L.Q.; Neamati, N. Med Res. Rev., 2008, 28, 118-154.
50. Grinsztein, B.; Nguyen, B-Y.; Katlama, C.; Gatell, J.M.; Lazzarin, A.; Vittecoq, D.; Gonzalez, C.; Chen, J.; Harvey, C.M.; Isaacs, R.D.; for the Protocol 005 Team. Lancet, 2007, 369, 1261-1269.
51. Markowitz, M.; Nguyen, B.Y.; Gotuzzo, E.; Mendo, F.; Ratanasuwan, W.; Kovacs, C.; Prada, G.; Morales-Ramirez, J.O.; Crumpacker, C.S.; Isaacs, R.D.; Gilde, L.R.; Wan, H.; Miller, M.D.; Wenning, L.A.; Teppler, H.; Protocol 004 Part II Study Team. J. Acquir. Immune Defic. Syndr., 2007, 46, 125-133.
52. Mathias, A.; Shen, G.; Enejosa, J.; Sekar, V.; Mack, R.; Tomaka, F.; Kearney, B. www.ias2007.org/pag/Abstracts.aspx?SID=48&AID= 4055.
53. Kilgore, N.; Reddick, M.; Zuiderhof, M.; Stanley, D.; Nitz, T.; Bullock, P.; Allaway, G.; Martin, D. www.ias2007.org/pag/ Abstracts.aspx?SID=48&AID=elementId=200702080.
54. Mascola, J.R.; Stiegler, G.; VanCott, T.C.; Katinger, H.; Carpenter, C.B.; Hanson, C.E.; Beary, H.; Hayes, D.; Frankel, S.S.; Birx, D.L; Lewis, M.G. Nat. Med., 2000, 6, 207-210.
55. Addo, M.M.; Draenert, R.; Rathod, A.; Verrill, C.L.; Davis, B.T.; Gandhi, R.T.; Robbins, G.K.; Basgoz, N.O.; Stone, D.R.; Cohen, D.E.; Johnston, M.N.; Flynn, T.; Wurcel, A.G.; Rosenberg, E.S.; Altfeld, M.; Walker, B.D. PLoS ONE, 2007, 2, e321.
56. Churchyard, G. http://www.DHHS/NTH/NIAD/DAIDS. (accessed December 29th 2007)
57. Kostense, S.; Koustaal, W.; Sprangers, M.; Weverling, G.J.; Penders, G.; Helmus, N.; Vogels, R.; Bakker, M.; Berkbout, B.; Havenga, M.; Goudsmit, J. AIDS, 2004, 18, 1213-1216.
58. Vogels, R.; Zuijdgeest, D.; Van Rijnsoever, R.; Hartkoorn, E.; Damen, I.; de Bethune, M.P.; Kostense, S.; Penders, G.; Helmus, N.; Koudstaal, W.; Cecchini, M.; Wetterwald, A.; Sprangers, M.; Lemckert, A.; Ophorst, O.; Koel, B.; van Meerendonk, M.; Quax, P.; Panitti, L.; Grimbergen, J.; Bout, A.; Goudsmit, J.; Havenga, M. J. Virol., 2003, 77, 8263-8271.
59. Stiegler, G.; Katinger, H. J. Antimicrob. Chemother., 2003, 51, 757-759.
60. Buchacher, A.; Predl, R.; Strutzenberger, K.; Steinfellner, W.; Trkola, A.; Purtscher, M.; Gruber, G.; Tauer, C.; Steindl, F.; Jungbauer, A.; on behalf the study group. AIDS Res. Hum. Retroviruses, 1994, 10, 359-369.
61. Armbruster, C.; Stiegler, G.M.; Vcelar, B.; Jäger, W.; Michael, N.L.; Vetter, N.; Katinger, H.W. AIDS, 2002, 16, 227-233.
62. Armbruster, C.; Stiegler, G.M.; Vcelar, B.A.; Jäger, W.; Köller, U.; Jilch, R.; Ammann, C.G.; Pruenster, M.; Stoiber, H.; Katinger, H.W. J. Antimicrob. Chemother., 2004, 54, 915-920.
63. Del Mar Gutierrez, M.; Mateo, G.; Domingo, P. Expert Opin. Pharmacother., 2007, 8, 1871-1884.
64. Law, M.; Puls, R.; Cheng, A.K.; Cooper, D.A.; Carr, A. Antivir. Ther., 2006, 11, 179-186.
65. Vaughn, G.; Detels, R. AIDS Care, 2007, 19, 492-499.
66. Worm, S.W.; Sabin, C.; Reiss, P.; El-Sadr, W.; D'Arminio Monforte, A.; Law, M.; Rickenback, M.; De Wit, S.; Lundgren, J.; Friis-Moller, N.; and The D:A:D Study Group. 14th Conference on Retroviruses and Opportunistic Infections, 2007, abstract 815.
67. Stöllberger, C.; Bonner, G.; Armbruster, C.; Gmeinhart, B.; Finsterer, J. AIDS, 2007, 21, 1064-1066.
68. Tural, C.; Ruiz, L.; Holtzer, C.; Shapiro, J.; Viciana, P.; Gonzalez, J.; Domingo, P.; Boucher, C.; Rey-Joly, C.; Clotet, B.; Havana Study Group. AIDS, 2002, 16, 209-218.
69. Piscitelli, S.C.; Gallicano, K.D. N. Engl. J. Med., 2001, 344, 984-996.
70. Acosta, E.P.; Gerber, J.G. AIDS Res. Hum. Retroviruses, 2002, 18, 825-834.
71. van Heeswijk, R.P. Ther. Drug Monit., 2002, 24, 323-331.
72. Joos, B.; Trkola, A.; Kuster, H.; Aceto, L.; Fischer, M.; Stiegler, G.; Armbruster, C.; Vcelar, B.; Katinger, H.; Günthard, H.F. Antimicrob. Agents Chemother., 2006, 50, 1773-1779.
73. Benson, C.A.; Vaida, F.; Havlir, D.V.; Downey, G.F.; Lederman, M.M.; Gulick, R.M.; Glesby, M.J.; Wantman, M.; Bixby, C.J.; Rinehart, A.R.; Snyder, S.; Wang, R.; Patel, S.; Mellors, J.W. J. Infect. Dis., 2006, 194, 1309-1318.
74. Strategies for the management of antiretroviral therapy (SMART) Study Group; E-Sadr, W.M.; Lundgren, J.D.; Neaton, J.D.; Gordin, F.; Abrams, D.; Arduino, R.C.; Babiker, A.; Burman, W.; Clumeck, N.; Cohen, C.J.; Cohn, D.; Cooper, D.; Darbyshire, J.; Emery, S.; Fätkenheuer, G.; Gazzard, B.; Grund, B.; Hoy, J.; Klingman, K.; Losso, M.; Markowitz, N.; Neuhaus, J.; Phillips, A.; Rappoport, C. N. Engl. J. Med., 2006, 355, 2283-2296.
75. Cohen, C.J.; Colson, A.E.; Sheble-Hall, A.G.; McLaughlin, K.A.; Morse, G.D. HIV Clin. Trials, 2007, 8, 19-23.
76. Buchacz, K.; Patel, P.; Taylor, M.; Kerndt P.R.; Byers R.H.; Holmberg S.D.; Klausner, J.D. AIDS, 2004, 18, 2075-2079.
77. Bailey, R.C.; Moses, S.; Parker, C.P.; Agot, K.; Maclean, I.; Krieger, J.N.; Williams, C.F.M.; Campbell, R.T.; Ndinya-Achola, J.O. Lancet, 2007, 369, 643-656.
78. Gray, R.H.; Kigozi, G.; Serwadda, D.; Makumbi, F.; Watya, S.; Nalugoda, F.; Kiwanuka, N.; Moulton, L.H.; Chaudbary, M.A.; Chen, M.Z.; Sewankambo, N.K.; Wabwire-Mangen, F.; Bacon, M.C.; Williams, C.F.M.; Opendi, P.; Reynolds, S.J.; Laeyendecker, O.; Quinn, T.C.; Wawer, M.J. Lancet, 2007, 369, 657-666.
79. Global Campaign for Microbicides. http://www.global-campaign.org/ cellulose-sulfate.htm.
80. The Future II Study Group. Lancet, 2007, 369, 1861-1868.
81. Armbruster, C. Expert Opin. Investig. Drugs, 2002, 11, 1139-1148.
82. Peterson, L.; Taylor, D.; Roddy, R.; Belai, G.; Phillips, P.; Nanda, K.; Grant, R.; Clarke, E.E.; Doh, A.S.; Ridzon, R.; Jaffe, H.S.; Cates, W. PLoS Clin. Trials, 2007, 25, e27.
83. Blish, C.A.; Blay, W.M.; Haigwood, N.L.; Overbaugh, J. Curr. HIV Res., 2007, 5, 578-587.
84. Kantarci, S.; Koulinska, I.N.; Aboud, S.; Fawzi, W.W.; Villamor, E. J. Acquir. Immune Defic. Syndr., 2007, 46, 651-654.
85. US Department of Health and Human Services. Available at http://AIDSinfo.nih.gov.